Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Stem Neoplasms | 10 | 2020 | 191 | 1.470 |
Why?
|
| Glioma | 15 | 2025 | 3503 | 0.870 |
Why?
|
| Brain Neoplasms | 15 | 2025 | 9118 | 0.800 |
Why?
|
| Neurofibromatosis 1 | 1 | 2022 | 561 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 25 | 2025 | 36743 | 0.540 |
Why?
|
| Anorexia Nervosa | 3 | 2018 | 1364 | 0.430 |
Why?
|
| Hormone Replacement Therapy | 1 | 2018 | 757 | 0.400 |
Why?
|
| Bone Marrow | 6 | 2022 | 2935 | 0.280 |
Why?
|
| Image Interpretation, Computer-Assisted | 6 | 2024 | 3390 | 0.270 |
Why?
|
| Benzimidazoles | 2 | 2022 | 864 | 0.250 |
Why?
|
| Fluorodeoxyglucose F18 | 4 | 2017 | 2055 | 0.240 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 7 | 2022 | 2815 | 0.240 |
Why?
|
| Temporal Muscle | 1 | 2023 | 36 | 0.220 |
Why?
|
| Contrast Media | 2 | 2016 | 5330 | 0.220 |
Why?
|
| Growth Charts | 1 | 2023 | 60 | 0.210 |
Why?
|
| Child | 31 | 2025 | 80917 | 0.210 |
Why?
|
| Knee | 2 | 2017 | 277 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 9015 | 0.190 |
Why?
|
| Adolescent | 27 | 2025 | 89169 | 0.170 |
Why?
|
| Transposition of Great Vessels | 2 | 2014 | 580 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2025 | 9419 | 0.160 |
Why?
|
| Perfusion Imaging | 1 | 2020 | 195 | 0.150 |
Why?
|
| Permeability | 2 | 2018 | 725 | 0.150 |
Why?
|
| Levonorgestrel | 1 | 2018 | 80 | 0.140 |
Why?
|
| Ethinyl Estradiol | 1 | 2018 | 114 | 0.140 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 259 | 0.140 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2018 | 277 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 11878 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 2059 | 0.130 |
Why?
|
| Bone Density | 3 | 2022 | 3573 | 0.120 |
Why?
|
| Child, Preschool | 15 | 2025 | 42669 | 0.120 |
Why?
|
| Retrospective Studies | 12 | 2025 | 81762 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2017 | 3780 | 0.110 |
Why?
|
| Cerebellar Neoplasms | 1 | 2018 | 591 | 0.110 |
Why?
|
| Adiposity | 2 | 2022 | 1895 | 0.110 |
Why?
|
| Benchmarking | 1 | 2020 | 1057 | 0.110 |
Why?
|
| Medulloblastoma | 1 | 2018 | 683 | 0.110 |
Why?
|
| Quinazolines | 3 | 2015 | 1373 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2014 | 2735 | 0.100 |
Why?
|
| Administration, Oral | 2 | 2018 | 4030 | 0.100 |
Why?
|
| Female | 34 | 2025 | 397192 | 0.100 |
Why?
|
| Absorptiometry, Photon | 3 | 2022 | 1758 | 0.100 |
Why?
|
| Drug Combinations | 1 | 2018 | 2089 | 0.090 |
Why?
|
| Male | 34 | 2025 | 364719 | 0.090 |
Why?
|
| Positron-Emission Tomography | 5 | 2017 | 6669 | 0.090 |
Why?
|
| Water | 3 | 2022 | 1421 | 0.090 |
Why?
|
| Humans | 44 | 2025 | 768166 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2020 | 10101 | 0.090 |
Why?
|
| Infant | 9 | 2025 | 36535 | 0.090 |
Why?
|
| Research Report | 1 | 2013 | 369 | 0.090 |
Why?
|
| ROC Curve | 1 | 2018 | 3628 | 0.080 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 259 | 0.080 |
Why?
|
| Prognosis | 6 | 2025 | 30010 | 0.080 |
Why?
|
| Adipose Tissue | 2 | 2022 | 3329 | 0.080 |
Why?
|
| Crohn Disease | 1 | 2022 | 2295 | 0.080 |
Why?
|
| Hypertensive Encephalopathy | 1 | 2009 | 9 | 0.080 |
Why?
|
| Ependymoma | 1 | 2012 | 328 | 0.080 |
Why?
|
| Equipment Failure Analysis | 1 | 2011 | 845 | 0.080 |
Why?
|
| Phantoms, Imaging | 3 | 2014 | 2512 | 0.080 |
Why?
|
| Weight-Bearing | 1 | 2011 | 534 | 0.080 |
Why?
|
| Knee Prosthesis | 1 | 2011 | 395 | 0.080 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2009 | 50 | 0.080 |
Why?
|
| Diffusion | 4 | 2017 | 815 | 0.070 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2015 | 928 | 0.070 |
Why?
|
| Disease Progression | 3 | 2020 | 13671 | 0.070 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 6847 | 0.070 |
Why?
|
| Algorithms | 3 | 2020 | 14164 | 0.060 |
Why?
|
| Brain Stem | 1 | 2010 | 859 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2016 | 3573 | 0.060 |
Why?
|
| Camptothecin | 3 | 2013 | 600 | 0.060 |
Why?
|
| Lumbar Vertebrae | 2 | 2022 | 1885 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 14729 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2018 | 12465 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2009 | 1429 | 0.050 |
Why?
|
| Cerebral Angiography | 1 | 2009 | 1264 | 0.050 |
Why?
|
| Infant Behavior | 1 | 2004 | 157 | 0.050 |
Why?
|
| Knee Joint | 1 | 2011 | 1683 | 0.050 |
Why?
|
| Survival Rate | 4 | 2025 | 12840 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 1737 | 0.050 |
Why?
|
| Histones | 2 | 2023 | 2601 | 0.050 |
Why?
|
| Femur Head | 1 | 2003 | 297 | 0.050 |
Why?
|
| Thalidomide | 1 | 2006 | 886 | 0.050 |
Why?
|
| Brain | 6 | 2005 | 27360 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2001 | 326 | 0.040 |
Why?
|
| Fingers | 1 | 2003 | 511 | 0.040 |
Why?
|
| Image Enhancement | 3 | 2005 | 2880 | 0.040 |
Why?
|
| Molecular Biology | 1 | 2023 | 573 | 0.040 |
Why?
|
| Anisotropy | 2 | 2014 | 1292 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 5703 | 0.040 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2014 | 2420 | 0.040 |
Why?
|
| Pons | 1 | 2019 | 242 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2013 | 3683 | 0.040 |
Why?
|
| Quinolones | 2 | 2011 | 389 | 0.040 |
Why?
|
| Cognition | 1 | 2014 | 7073 | 0.030 |
Why?
|
| Brain Edema | 1 | 2001 | 601 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2022 | 1149 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2006 | 2056 | 0.030 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 1904 | 0.030 |
Why?
|
| Movement | 1 | 2003 | 1490 | 0.030 |
Why?
|
| Cerebellum | 1 | 2003 | 1522 | 0.030 |
Why?
|
| Motor Cortex | 1 | 2003 | 1013 | 0.030 |
Why?
|
| Models, Biological | 1 | 2011 | 9495 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 20227 | 0.030 |
Why?
|
| Biological Availability | 1 | 2015 | 389 | 0.030 |
Why?
|
| Ischemia | 1 | 2003 | 1900 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2004 | 2124 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2018 | 771 | 0.030 |
Why?
|
| Ice | 1 | 2014 | 102 | 0.030 |
Why?
|
| Moyamoya Disease | 1 | 1997 | 274 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 15454 | 0.030 |
Why?
|
| Cerebrovascular Circulation | 2 | 2009 | 2725 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6526 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2011 | 8542 | 0.030 |
Why?
|
| Young Adult | 5 | 2024 | 60066 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2019 | 5315 | 0.030 |
Why?
|
| Child Development | 1 | 2004 | 2330 | 0.020 |
Why?
|
| Brain Diseases | 1 | 2001 | 1554 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 4120 | 0.020 |
Why?
|
| Goats | 1 | 2011 | 166 | 0.020 |
Why?
|
| Glioblastoma | 1 | 2006 | 3464 | 0.020 |
Why?
|
| Lipids | 1 | 2022 | 3343 | 0.020 |
Why?
|
| Age Factors | 3 | 2017 | 18412 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1703 | 0.020 |
Why?
|
| Radiography | 2 | 2011 | 6983 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 10760 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 2000 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2022 | 8741 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2015 | 2357 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 39348 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2004 | 6685 | 0.020 |
Why?
|
| Osteolysis | 1 | 2010 | 274 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 640 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 547 | 0.020 |
Why?
|
| Mutation | 2 | 2023 | 30238 | 0.020 |
Why?
|
| Neuropsychological Tests | 2 | 2014 | 7140 | 0.020 |
Why?
|
| Treatment Outcome | 4 | 2019 | 65371 | 0.020 |
Why?
|
| Infant, Newborn | 4 | 2013 | 26422 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2012 | 1273 | 0.020 |
Why?
|
| Executive Function | 1 | 2014 | 1401 | 0.020 |
Why?
|
| Tibia | 1 | 2011 | 1076 | 0.020 |
Why?
|
| Time Factors | 3 | 2015 | 40218 | 0.020 |
Why?
|
| Femur | 1 | 2011 | 1321 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2005 | 363 | 0.010 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2010 | 952 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 2916 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2004 | 367 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2010 | 1502 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2013 | 22291 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2007 | 794 | 0.010 |
Why?
|
| Adult | 9 | 2014 | 223646 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2025 | 24315 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2018 | 8080 | 0.010 |
Why?
|
| Infant Care | 1 | 2004 | 182 | 0.010 |
Why?
|
| Intensive Care, Neonatal | 1 | 2004 | 200 | 0.010 |
Why?
|
| Epiphyses | 1 | 2003 | 191 | 0.010 |
Why?
|
| Internal Capsule | 1 | 2001 | 138 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 1587 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 2661 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9374 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 4063 | 0.010 |
Why?
|
| Obesity | 1 | 2022 | 13090 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8317 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 15948 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 11095 | 0.010 |
Why?
|
| HIV Infections | 1 | 2004 | 17569 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 3436 | 0.010 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2004 | 1489 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12543 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 6229 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2018 | 41754 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2020 | 54926 | 0.010 |
Why?
|
| Research Design | 1 | 2011 | 6211 | 0.010 |
Why?
|
| Choline | 1 | 1997 | 522 | 0.010 |
Why?
|
| Creatine | 1 | 1997 | 427 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1997 | 577 | 0.010 |
Why?
|
| Learning | 1 | 2004 | 1759 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 1997 | 823 | 0.010 |
Why?
|
| Reference Values | 1 | 2001 | 4938 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 9263 | 0.010 |
Why?
|
| Swine | 1 | 2003 | 5995 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1997 | 1140 | 0.010 |
Why?
|
| Biomedical Research | 1 | 2007 | 3463 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2004 | 6314 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2010 | 13676 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1997 | 4194 | 0.000 |
Why?
|
| Animals | 2 | 2011 | 169246 | 0.000 |
Why?
|
| Risk Factors | 1 | 2013 | 74944 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 5812 | 0.000 |
Why?
|
| United States | 1 | 2007 | 73039 | 0.000 |
Why?
|
Concepts
(189)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(60)
People in Profiles who have published with this person.
Explore
_
Similar People
(59)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_